Selenium-Based Novel Epigenetic Regulators Offer Effective Chemotherapeutic Alternative with Wider Safety Margins in Experimental Colorectal Cancer

2021 ◽  
Author(s):  
Preety Ghanghas ◽  
Monika Sharma ◽  
Dhimant Desai ◽  
Kaisar Raza ◽  
Aman Bhalla ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Safety Margins ◽  
Epigenetic Regulators

scholarly journals Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet–gene interactions and promoter CpG island hypermethylation in colorectal cancer

2010 ◽  
Vol 22 (1) ◽  
pp. 1-12 ◽  
Author(s):  
Stefan de Vogel ◽  
Kim A. D. Wouters ◽  
Ralph W. H. Gottschalk ◽  
Frederik J. van Schooten ◽  
Anton F. P. M. de Goeij ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cpg Island ◽  
Gene Interactions ◽  
Metabolizing Enzymes ◽  
Methyl Donors ◽  
Epigenetic Regulators

scholarly journals Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer

2009 ◽  
Vol 18 (11) ◽  
pp. 3086-3096 ◽  
Author(s):  
Stefan de Vogel ◽  
Kim A.D. Wouters ◽  
Ralph W.H. Gottschalk ◽  
Frederik J. van Schooten ◽  
Anton F.P.M. de Goeij ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Genetic Variants ◽  
Cpg Island ◽  
Metabolizing Enzymes ◽  
Epigenetic Regulators

scholarly journals Tumor-suppressive function of EZH2 is through inhibiting glutaminase

2021 ◽  
Vol 12 (11) ◽  
Author(s):  
Yongfeng Liu ◽  
Cheng-e Tu ◽  
Xuxue Guo ◽  
Changjie Wu ◽  
Chuncai Gu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Progression ◽  
Critical Role ◽  
Glucose Deprivation ◽  
Metabolic Reprogramming ◽  
Glutamine Metabolism ◽  
Metabolic Adaptation ◽  
Ezh2 Expression ◽  
Epigenetic Regulators ◽  
Tumor Suppressive Function

AbstractTumors can use metabolic reprogramming to survive nutrient stress. Epigenetic regulators play a critical role in metabolic adaptation. Here we screened a sgRNA library to identify epigenetic regulators responsible for the vulnerability of colorectal cancer (CRC) cells to glucose deprivation and found that more EZH2-knockout cells survived glucose deprivation. Then, we showed that EZH2 expression was significantly downregulated in response to glucose deprivation in a glucose-sensitive CRC cell line, and EZH2-knockdown cells were more resistant to glucose deprivation. Mechanistically, EZH2 deficiency upregulated the expression of glutaminase (GLS) and promoted the production of glutamate, which in turn led to increased synthesis of intracellular glutathione (GSH) and eventually attenuated the reactive oxygen species (ROS)-mediated cell death induced by glucose deprivation. Although EZH2 functioned as an oncogene in cancer progression and EZH2 knockout abolished colorectal cancer development in a mouse model, here we revealed a mechanistic link between EZH2 and metabolic reprogramming via the direct regulation of GLS expression and observed a negative correlation between EZH2 and GLS expression in colorectal cancer tissues. These findings further confirmed the importance of heterogeneity, provided an explanation for the clinical tolerance of cancer cells to EZH2 inhibitors from the perspective of metabolism, and proposed the possibility of combining EZH2 inhibitors and glutamine metabolism inhibitors for the treatment of cancer.

Deletion mapping on chromosome 6 in colorectal cancer associated with ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Deletion Mapping ◽  
Chromosome 6

Predicting adherence to colorectal cancer surveillance after plypectomy

2001 ◽  
Vol 120 (5) ◽  
pp. A602-A602
Author(s):  
S RAWL ◽  
S BLACKBURN ◽  
L HACKWARD ◽  
N FINEBERG ◽  
T IMPERIALE ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Surveillance ◽  
Colorectal Cancer Surveillance

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type

A panel of mono- and dinucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A599
Author(s):  
C ARNOLD ◽  
A GOEL ◽  
J CARETHERS ◽  
L WASSERMAN ◽  
C COMPTON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Markers ◽  
Reliable Determination

Use of plasma MMP-2 to measure response to surgery and chemoradiotherapy in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A159-A159
Author(s):  
M TUTTON ◽  
M GEORGE ◽  
S ECCLES ◽  
I SWIFT ◽  
M ABULAFI
Keyword(s):  
Colorectal Cancer

Adjuvant intraportal chemotherapy for dukes B2 or C colorectal cancer also receiving systemic treatment

2001 ◽  
Vol 120 (5) ◽  
pp. A611-A611
Author(s):  
S ROLAND ◽  
J BURY ◽  
C FOCAN
Keyword(s):  
Colorectal Cancer ◽  
Systemic Treatment
Sign in / Sign up

Export Citation Format

Share Document